Research Information System
in: Romatolojik Hastalıklarda Biyolojik Ajanlar ve Kinaz İnhibitörlerine Genel Bakış - 2022, Prof. Dr. Timuçin KAŞİFOĞLU,Prof. Dr. N. Şule YAŞAR BİLGE, Editor, Türkiye Klinikleri Yayınevi, Ankara, pp.51-57, 2022
Interleukin 17 (IL-17) is involved in the pathogenesis of spondyloarthritis (SpA) and targeting of this cytokine have given new insights in the treatment of SpA. IL-17 targeting agents documented have same efficacy and safety with TNF blockers. In this study, in the light of the recent literature, we reviewed the safety data of IL-17 targeting treatments and pointed out the undesired adverse events hat could be seen during the therapy.